KNSA Kiniksa Pharmaceuticals Ltd.

10.61
+0.64  (+6%)
Previous Close 9.97
Open 11.54
Price To Book 2.31
Market Cap 582,291,017
Shares 54,881,340
Volume 386,989
Short Ratio
Av. Daily Volume 216,087
Stock charts supplied by TradingView

NewsSee all news

  1. Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

    HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th,

  2. Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

    HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic

  3. Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

    - Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores -- Tapering and discontinuation of corticosteroids without pericarditis recurrence - - Markedly lower annualized

  4. Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting

    - Mavrilimumab suppresses pathogenic immune responses in a validated in vivo model of medium and large vessel vasculitis - - Additional human ex vivo data support rationale for targeting GM-CSF in GCA - HAMILTON,

  5. Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

    – Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 –– Operating plan funded into 2H 2021; no current plan to raise additional capital prior to delivering clinical data

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2H 2020.
Rilonacept (RHAPSODY)
Pericarditis
Phase 2 data due 2H 2020.
Mavrilimumab
Giant cell arteritis (GCA)
Phase 1b data showed no meaningful benefit - August 12, 2019.
KPL-716
Atopic dermatitis
Phase 2 data due 1H 2020.
KPL-716
Prurigo nodularis
Phase 2 interim data due 1H 2020.
KPL-716
Chronic Pruritus

Latest News

  1. Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

    HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th,

  2. Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

    HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic

  3. Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

    - Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores -- Tapering and discontinuation of corticosteroids without pericarditis recurrence - - Markedly lower annualized

  4. Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting

    - Mavrilimumab suppresses pathogenic immune responses in a validated in vivo model of medium and large vessel vasculitis - - Additional human ex vivo data support rationale for targeting GM-CSF in GCA - HAMILTON,

  5. Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

    – Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 –– Operating plan funded into 2H 2021; no current plan to raise additional capital prior to delivering clinical data

  6. Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

    HAMILTON, Bermuda, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic